Hematology (all articles) | Page 26 of 50 | Links Medicus Content Curation & Alerts in Medicine

Study finds low risk of venous thromboembolism in outpatients with Covid-19 – researchers advise against the use of anticoagulants outside clinical trials

8 Apr, 2021 | 08:59h | UTC

Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California – JAMA Internal Medicine

Commentaries: VTE Related to SARS-CoV-2 Infection Less Of a Problem in Outpatients – TCTMD AND No Increase Seen in Outpatient VTE for SARS-CoV-2-Positive Patients – Physician’s Weekly

Commentary on Twitter (thread – Click for more)

https://twitter.com/gjgeersing/status/1379740743951134721

Guidance on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination

7 Apr, 2021 | 01:48h | UTC

Guidance produced from the Expert Haematology Panel (EHP) focussed on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination – British Society of Haematology

Commentary on Twitter

https://twitter.com/trishgreenhalgh/status/1379414362700517385

Large study showed no association between blood group types and increased risk of Covid-19

7 Apr, 2021 | 01:41h | UTC

Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population – JAMA Network Open

Commentary on Twitter

This case-control study found blood type A was not associated with higher nor type O with lower COVID-19 susceptibility or severity. Blood types were not prognostically useful. https://t.co/P8VpvQWuwE

— JAMA Network Open (@JAMANetworkOpen) April 6, 2021

Recent progress in the treatment of cancer in children

5 Apr, 2021 | 01:15h | UTC

Recent progress in the treatment of cancer in children – CA: A Cancer Journal for Clinicians

Cohort Study: DOACs Safe, Effective in Subset of Valvular AF Patients

5 Apr, 2021 | 01:10h | UTC

DOACs Safe, Effective in Subset of Valvular AF Patients – TCTMD

Original study: Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation: A Population-Based Cohort Study – Annals of Internal Medicine

Cohort study: High thrombotic risk in cancer patients receiving immunotherapy

5 Apr, 2021 | 01:08h | UTC

High thrombotic risk in cancer patients receiving immunotherapy – Medical University of Vienna

Original study: Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy – Blood

Exceedingly rare side effects reported with AstraZeneca vaccine in the UK – 22 cases of cerebral venous sinus thrombosis with low levels of platelets out of 18 million vaccinated individuals

5 Apr, 2021 | 01:45h | UTC

Covid-19: Seven UK blood clot deaths after AstraZeneca vaccine – BBC

Original report: Coronavirus vaccine – weekly summary of Yellow Card reporting – Medicines and Healthcare products Regulatory Agency

“Based on current experience, the expected benefits of both COVID-19 vaccines in preventing COVID-19 and its serious complications far outweigh any known side effects”

Preliminary study finds a low-calorie diet and mild exercise may improve survival for young people with leukemia

2 Apr, 2021 | 09:12h | UTC

Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial – Blood Advances

Commentary: Low-calorie diet and mild exercise improve survival for young people with leukemia – University of California, Los Angeles (UCLA)

M-A: Fracture risk is lower in patients anticoagulated with NOACs compared to patients treated with warfarin

26 Mar, 2021 | 08:26h | UTC

Fracture Risks in Patients Treated With Different Oral Anticoagulants: A Systematic Review and Meta‐Analysis – Journal of the American Heart Association

Commentary: NOACs associated with a 16% lower risk of bone fractures than warfarin – Cardiovascular Business

Systematic review: Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease

23 Mar, 2021 | 02:09h | UTC

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease – Cochrane Library

RCT: Pegcetacoplan vs. Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

21 Mar, 2021 | 21:32h | UTC

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review

21 Mar, 2021 | 21:49h | UTC

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review – Journal of the American College of Cardiologyv

Commentary on Twitter

@JACCJournals: We share a systematic summary of #anticcogulation,#antiplatelet, and #fibrinolysis #RCTs in #COVID19. Amazing work by @AzitaTalasaz and a stellar multidisciplinary team! Figs illustrate areas where we’ll have evidence, & the gaps. Link: https://t.co/t4ksxwjAze pic.twitter.com/0Th3OZBXOY

— Behnood Bikdeli (@bbikdeli) March 16, 2021

RCT: Intermediate-dose enoxaparin (1 mg/kg/d) not better than standard-dose prophylactic anticoagulation in patients with Covid-19 admitted to the intensive care unit

19 Mar, 2021 | 08:42h | UTC

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial – JAMA

Editorial: Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19 – JAMA

Commentary on Twitter

Intermediate-dose prophylactic enoxaparin (1 mg/kg/d) had no effect on a primary composite outcome of adjudicated venous or arterial thrombosis, ECMO, or 30-d mortality vs standard dose enoxaparin among ICU patients w #COVID19 https://t.co/L6UdB31J7V

— JAMA (@JAMA_current) March 18, 2021

Opinion | “’It’s a very special picture.’ Why vaccine safety experts put the brakes on AstraZeneca’s COVID-19 vaccine”

18 Mar, 2021 | 09:14h | UTC

‘It’s a very special picture.’ Why vaccine safety experts put the brakes on AstraZeneca’s COVID-19 vaccine – Science (a few articles per month are free)

Related: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries)

Opinion | “Oxford-AstraZeneca Vaccine Safety: Reports of blood clots after receiving the AstraZeneca COVID-19 vaccine are very likely just background events.”

18 Mar, 2021 | 09:09h | UTC

Oxford-AstraZeneca Vaccine Safety: Reports of blood clots after receiving the AstraZeneca COVID-19 vaccine are very likely just background events. – Science-Based Medicine

Platelet tests pre-CABG may safely shorten washout waits, cut costs

16 Mar, 2021 | 01:44h | UTC

Platelet Tests Pre-CABG May Safely Shorten Washout Waits, Cut Costs – TCTMD

Original study: Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization – Journal of the American College of Cardiology

[Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19

14 Mar, 2021 | 20:59h | UTC

Therapeutic Anticoagulation in Critically Ill Patients with Covid-19-Preliminary Report – medRxiv

Commentary: PulmCrit Wee – Therapeutic anticoagulation for COVID ICU patients: Is the heparin vial half empty, or half full?

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots

12 Mar, 2021 | 08:32h | UTC

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots – The BMJ

Commentary on Twitter

Denmark has temporarily suspended use of the Oxford-AstraZeneca covid-19 vaccine as a precautionary move after reports of blood clots. But the EMA and the UK’s regulatory body say there is no indication that vaccination is linked to thromboembolic events https://t.co/sW8GRqcnLg

— The BMJ (@bmj_latest) March 11, 2021

[Preprint] RECOVERY trial: Convalescent plasma does not improve outcomes in patients admitted to hospital with COVID-19

11 Mar, 2021 | 08:43h | UTC

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv

Commentary on Twitter (thread – click for more)

RECOVERY Pre-print:

Convalescent plasma does not improve survival in patients hospitalised with COVID-19 in this randomised controlled trial involving 11,558 patients:https://t.co/36YZwJNY3Q pic.twitter.com/sKR095n1PC

— Martin Landray (@MartinLandray) March 10, 2021

NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms

3 Mar, 2021 | 08:55h | UTC

NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms – National Institutes of Health

RCT: Effect of Blinatumomab vs. Chemotherapy in children with high-risk first-relapse B-Cell Acute Lymphoblastic Leukemia

3 Mar, 2021 | 08:19h | UTC

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia – JAMA (free for a limited period)

M-A: Treatment with convalescent plasma is not associated with better outcomes in patients with Covid-19

28 Feb, 2021 | 21:51h | UTC

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis – JAMA

Editorial: Emerging Lessons From COVID-19 for the US Clinical Research Enterprise

Commentary on Twitter

Just out: Our meta-analysis in @JAMA_current

"Among patients with COVID-19, treatment with convalescent plasma compared with control was not associated with improved survival or other positive clinical outcomes"https://t.co/tRqpd9v67m

— Lars G. Hemkens (@LGHemkens) February 26, 2021